SCHEMBL123055

SCHEMBL123055

N[C@@H](CC(=O)O)Cc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.64
CPA1 P15085 2/20 0.60
CPB1 P15086 1/20 0.60
CPA3 P15088 1/20 0.60
CPB2 Q96IY4 1/20 0.60
ALPI P09923 1/20 0.59
PKM P14618 1/20 0.59
PTGS1 P23219 1/20 0.59
XIAP P98170 1/20 0.59
SLC7A5 Q01650 1/20 0.59
ANPEP P15144 3/20 0.55
SLC15A1 P46059 1/20 0.55
MMP2 P08253 2/20 0.54
SLC1A3 P43003 2/20 0.53
SLC1A2 P43004 2/20 0.53
SLC1A1 P43005 2/20 0.53
DPP4 P27487 1/20 0.53
CYP1A2 P05177 1/20 0.52
LTA4H P09960 1/20 0.51
LAP3 P28838 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197907 1.00 EPHX1 (0.64) EPHX1CPA1CPB1CPA3CPB2
SCHEMBL287736 1.00 EPHX1 (0.64) EPHX1CPA1CPB1CPA3CPB2
Hydrochloric Acid SCHEMBL654577 0.98 EPHX1 (0.61) EPHX1CPA1CPB1CPA3CPB2
Hydrochloric Acid SCHEMBL654576 0.98 EPHX1 (0.61) EPHX1CPA1CPB1CPA3CPB2
Acetic Acid SCHEMBL6690172 0.94 ALPI (0.58) EPHX1CPA1CPB1CPA3CPB2
Trifluoroacetic Acid SCHEMBL1395876 0.91 EPHX1 (0.53) EPHX1CPA1CPB1CPA3CPB2
Trifluoroacetic Acid SCHEMBL6157790 0.91 EPHX1 (0.53) EPHX1CPA1CPB1CPA3CPB2
SCHEMBL29556848 0.89 FFAR1 (0.55) EPHX1CPA1CPB1CPA3CPB2
SCHEMBL2032416 0.89 FFAR1 (0.55) EPHX1CPA1CPB1CPA3CPB2
Hydrochloric Acid SCHEMBL1912599 0.87 SRR (0.55) EPHX1CPA1CPB1CPA3CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117915957-A Compositions and methods for modulating mRNA splicing 恩特拉达治疗学股份有限公司 2024-04-19 CN claimed
EP-4337676-A1 ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS Entrada Therapeutics, Inc. (US) 2024-03-20 EP claimed
CN-117561271-A Cyclic cell penetrating peptides 恩特拉达治疗公司 2024-02-13 CN claimed
WO-2023219933-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS ENTRADA THERAPEUTICS, INC. (US) 2023-11-16 WO claimed
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2023-04-13 US claimed
US-11001609-B2 Cell permeable cyclic peptide scaffolds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-05-11 US claimed
CN-111655294-A Ligand-drug-conjugates as substrates for selective cleavage by cathepsin B peptidase activity 德比欧药物研究有限公司 2020-09-11 CN claimed
US-20200157149-A1 Cell Permeable Cyclic Peptide Scaffolds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-05-21 US claimed
US-9982015-B2 Cyclin based inhibitors of CDK2 and CDK4 UNIVERSITY OF SOUTH CAROLINA (US) 2018-05-29 US claimed
US-9896481-B2 Modified mini-hepcidin peptides and methods of using thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-02-20 US claimed
US-8580997-B2 Process for preparing R-beta-amino phenylbutyric acid derivatives JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2013-11-12 US claimed
US-8466108-B2 TFPI inhibitors and methods of use BAXTER INTERNATIONAL INC. (US) 2013-06-18 US claimed
WO-2012150495-A1 SYNTHETIC PEPTIDES AND RANDOM COPOLYMERS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS NATIONAL INSTITUTE OF IMMUNOLOGY (IN) 2012-11-08 WO claimed
EP-2379096-A2 TFPI INHIBITORS AND METHODS OF USE Baxter International Inc. (US) 2011-10-26 EP claimed
US-20110130587-A1 PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2011-06-02 US claimed
EP-2308829-A1 A PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES Jiangsu Hengrui Medicine Co., Ltd. (CN) 2011-04-13 EP claimed
WO-2010071894-A2 TFPI INHIBITORS AND METHODS OF USE BAXTER INTERNATIONAL INC. (US) 2010-06-24 WO claimed
EP-1882740-B1 N-acetyl-(R,S)-B-amino acid acylase gene AJINOMOTO KK (JP) 2010-04-14 EP claimed
US-20080241895-A1 N-Acetyl-(R,S)-beta-Amino Acid Acylase Gene AJINOMOTO CO., INC. (JP) 2008-10-02 US claimed
EP-1882740-A1 N-acetyl-(R,S)-B-amino acid acylase gene Ajinomoto Co., Ltd. (JP) 2008-01-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11001609-B2 Cell permeable cyclic peptide scaffolds VIP, IAPP, HM13 EPHX1 4192/4885CPA1 354/4885CPB1 553/4885
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF TST, ABAT, AADAC EPHX1 3317/4885CPA1 1085/4885CPB1 109/4885
US-20080241895-A1 N-Acetyl-(R,S)-beta-Amino Acid Acylase Gene ACSL4, FASN, BLVRB EPHX1 3502/4885CPA1 2925/4885CPB1 631/4885
US-20110130587-A1 PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES ALAD, DAO, DDO EPHX1 3050/4885CPA1 2059/4885CPB1 1032/4885
US-20200157149-A1 Cell Permeable Cyclic Peptide Scaffolds VIP, IAPP, HM13 EPHX1 4192/4885CPA1 354/4885CPB1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.